Effects of oncogenic Gαq and Gα11 inhibition by FR900359 in uveal melanoma

Dominic Lapadula, Eduardo Farias, Clinita E. Randolph, Timothy J. Purwin, Dougan McGrath, Thomas H. Charpentier, Lihong Zhang, Shihua Wu, Mizue Terai, Takami Sato, Gregory G. Tall, Naiming Zhou, Philip B. Wedegaertner, Andrew E. Aplin, Julio Aguirre-Ghiso, Jeffrey L. Benovic

Research output: Contribution to journalArticlepeer-review

58 Scopus citations


Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating mutations in the G proteins, Gaq and Ga11, are observed in approximately 93% of all uveal melanomas. Although therapeutic intervention of downstream Gaq/11 targets has been unsuccessful in treating uveal melanoma, we have found that the Gaq/11 inhibitor, FR900359 (FR), effectively inhibits oncogenic Gaq/11 signaling in uveal melanoma cells expressing either mutant Gaq or Ga11. Inhibition of oncogenic Gaq/11 by FR results in cell-cycle arrest and induction of apoptosis. Furthermore, colony formation is prevented by FR treatment of uveal melanoma cells in 3D-cell culture, providing promise for future in vivo studies. This suggests direct inhibition of activating Gaq/11 mutants may be a potential means of treating uveal melanoma. Implications: Oncogenic Gaq/11 inhibition by FR900359 may be a potential treatment option for those with uveal melanoma.

Original languageEnglish
Pages (from-to)963-973
Number of pages11
JournalMolecular Cancer Research
Issue number4
StatePublished - 2019


Dive into the research topics of 'Effects of oncogenic Gαq and Gα11 inhibition by FR900359 in uveal melanoma'. Together they form a unique fingerprint.

Cite this